Therapy with renin-angiotensin system blockers after pulmonary vein isolation in patients with atrial fibrillation: Who is a responder?

PACE - Pacing and Clinical Electrophysiology

Volumn 33, Issue 9, 2010, Pages 1101-1111

  Berkowitsch, Alexander ^a   Neumann, Thomas ^a   Kuniss, Malte ^a   Janin, Sebastien ^a   Wojcik, MacIej ^a   Zaltsberg, Sergej ^a   Mitrovic, Veselin ^a   Pitschner, Heinz F ^a  

^a KERCKHOFF HEART CENTER   (Germany)

Author keywords

angiotensin receptor blockers; angiotensin converting enzyme inhibitors; atrial fibrillation; pulmonary vein isolation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CATHETER ABLATION; CORONARY ARTERY DISEASE; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HOLTER MONITORING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PULMONARY VEIN ISOLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINUS RHYTHM;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CATHETER ABLATION; COHORT STUDIES; DIURETICS; ELECTROCARDIOGRAPHY, AMBULATORY; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PULMONARY VEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; STROKE VOLUME; TREATMENT OUTCOME;

EID: 77956321323     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2010.02769.x     Document Type: Article

References (21)

1. Wijfels M, Kirchhof C, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995 92 : 1954 1968.
2. Goette A, Staack T, Röcken C, Arndt M, Geller JC, Huth C, Ansorge S, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000 35 : 1669 1677.
3. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodelling in atrial fibrillation. J Am Coll Cardiol 2003 41 : 2197 2204.
4. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J Am Coll Cardiol 2005 45 : 1832 1839.
5. Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009 360 : 1606 1617.
6. Gillis AM. Angiotensin-receptor blockers for prevention of atrial fibrillation - a matter of timing or target? N Engl J Med 2009 360 : 1669 1671.
7. Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte ML, Perlini S. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009 53 : 24 29.
8. Al Chekakie MO, Akar JG, Wang F, Al Muradi H, Wu J, Santucci P, Varma N, et al. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 2007 18 : 942 946.
9. Richter B, Derntl M, Marx M, Lercher P, Gössinger HD. Therapy with angiotensin-converting enzyme inhibitors. Angiotensin II receptor blockers, and statins no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007 153 : 113 119.
10. Rotter M, Jaïs P, Garrigue S, Sanders P, Hocini M, Hsu LF, Takahashi Y, et al. Clinical predictors of noninducibility of sustained atrial fibrillation after pulmonary vein isolation. J Cardiovasc Electrophysiol 2005 16 : 1298 1303.
11. Brooks A, Namboodiri N, Sanders P. Clinical characteristics to guide the extent of ablation in paroxysmal AF patients discovering an old science. Indian Pacing Electrophysiol J 2009 9 : 134 137.
12. Berkowitsch A, Neumann T, Kuniss M, Brandt R, Zaltsberg S, Pitschner HF. Evaluation of atrial fibrillation burden before catheter ablation predicts outcome after pulmonary vein isolation. Indian Pacing Electrophysiol J 2009 9 : 138 150.
13. Neumann T, Vogt J, Schumacher B, Dorszewski A, Kuniss M, Neuser H, Kurzidim K, et al. Circumferential pulmonary vein isolation with the cryoballoon technique. Results from a prospective three center study. J Am Coll Cardiol 2008 52 : 273 278.
14. Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, Tsang TS. Left atrial size physiologic determinants and clinical applications. J Am Coll Cardiol 2006 47 : 2357 2363.
15. Lam TK, Leung DT. More on simplified calculation of body-surface area. N Engl J Med 1988 318 : 1130.
16. Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 2008 51 : 1 11.
17. Letsas KP, Weber R, Bürkle G, Mihas CC, Minners J, Kalusche D, Arentz T. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation the potential role of inflammation. Europace 2009 11 : 158 163.
18. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation clinical and experimental evidence. Eur Heart J 2006 27 : 512 518.
19. Deneke T. ARBs, ACE-Is, or statins after catheter ablation of atrial fibrillation? J Cardiovasc Electrophysiol 2007 18 : 947 949.
20. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, Carluccio E, et al. Atrial fibrillation in hypertension; predictors and outcome. Hypertension 2003 41 : 218 223.
21. Healey S, Connolly S. Atrial fibrillation hypertension as a causative agent. Risk factor for complications, and potential therapeutic target. Am J Cardiol 2003 91 : 9 14.